COMMUNIQUÉS West-GlobeNewswire

XBiotech annonce que le Dr Alice Gottlieb dirigera la prochaine étude de phase 2 sur le bermekimab pour le traitement de l'hidradénite suppurée
26/06/2019
AUSTIN, Texas, 26 juin 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ : XBIT) annonce qu'Alice Gottlieb, M.D., Ph.D., dirigera la prochaine étude de phase 2 de la société portant sur l'hidradénite suppurée (HS). Le Dr [...]
Biohit Colonview Quick Test product improvement – a new Control reagent
26/06/2019
Biohit Oyj Press release 26.6.2019 at 14.15 local time (EEST) Biohit Colonview® quick test is now available with a control reagent. Biohit ColonView QT Control (Cat. No. 602390) is intended as a positive quality control [...]
Finnish Spinal Cord Injury Rehabilitation Research Using Nexstim SmartFocus Technology Receives Significant Funding from Wings for Life Foundation
26/06/2019
Press Release, Helsinki, 26 June 2019 at 2.15 pm (EET) Finnish Spinal Cord Injury Rehabilitation Research Using Nexstim SmartFocus TM Technology Receives Significant Funding from Wings for Life Foundation Nexstim Plc ( [...]
Amunix Pharmaceuticals Announces the Appointment of Dr. Bryan Irving as Chief Scientific Officer
26/06/2019
MOUNTAIN VIEW, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating biotherapeutics in solid tumors, [...]
Akcea and Ionis Announce Upcoming Data Presentations at the 5th European Academy of Neurology Annual Congress
26/06/2019
Multiple clinical presentations focus on the long-term clinical benefits of treatment with TEGSEDI® (inotersen) BOSTON and CARLSBAD, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an [...]
Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAᵀᴹ (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC)
26/06/2019
Completed Phase 1 trial in patients with hepatic impairment established Oral KORSUVA tablet strength STAMFORD, Conn., June 26, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company [...]
Translate Bio Announces FDA Clearance to Proceed with a Single-ascending Dose (SAD) Phase 1/2 Clinical Trial for Ornithine Transcarbamylase (OTC) Deficiency
26/06/2019
LEXINGTON, Mass., June 26, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat [...]
Teleflex Announces Expanded Nationwide Coverage for the UroLift System for Patients with Enlarged Prostate
26/06/2019
Coverage Decision by Anthem Increases Access to Minimally Invasive Treatment, Offering Patients Rapid, Durable Symptom Relief WAYNE, Pa., June 26, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today [...]
Steven A. Schwartz Joins Exactus Board of Directors
26/06/2019
DELRAY BEACH, Fla., June 26, 2019 (GLOBE NEWSWIRE) -- Exactus Inc. (OTCQB: EXDI) – a healthcare company pursuing opportunities in Hemp derived Cannabidiol (CBD) products, is pleased to announce the appointment of Steven [...]
Philips completes cancellation of 30.0 million shares
26/06/2019
June 26, 2019 Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it has completed the cancellation of 30,000,000 of its shares. The cancelled shares were acquired as part of Philips’ [...]
RavenQuest Provides Corporate Update
26/06/2019
VANCOUVER, British Columbia, June 26, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) is pleased to provide the following full update on all [...]
Change in the Terveystalo Plc Executive team: Johanna Karppi, SVP of HR to leave the company
26/06/2019
Terveystalo Plc. Stock Exchange Release 26 June 2019 at 12:00 EEST Johanna Karppi, Senior Vice President, HR, has decided to leave Terveystalo as of 1 October 2019 to join Finnair, Finnish airline. Terveystalo has [...]
Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome
26/06/2019
Press release – No. 16 / 2019 Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome Short bowel syndrome (SBS) is a complex [...]
Oasmia presents full-year report and status in the Board's review through audiocast on June 28
26/06/2019
Oasmia will hold an audiocast and telephone conference on Friday 28 June at 09:00 (CET) to present the company's full-year report for the financial year 2018/2019 and the status of the board's previously communicated [...]
DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical Officer
26/06/2019
Montrouge, France, June 26, 2019 DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical Officer Dr. Mohideen brings extensive experience in clinical drug development Dr. Hugh Sampson to [...]
DBV Technologies annonce la nomination du Docteur Pharis Mohideen au poste de Directeur Médical
26/06/2019
Montrouge, France, le 26 juin (7 h 30 CEST) 2019 DBV Technologies annonce la nomination du Docteur Pharis Mohideen au poste de Directeur Médical Le Docteur Mohideen possède une vaste expérience dans le développement [...]
Innate Pharma announces publication of IPH4102 Phase I clinical trial results for CTCL in the Lancet Oncology
26/06/2019
INNATE PHARMA ANNOUNCES PUBLICATION OF IPH4102 PHASE I CLINICAL TRIAL RESULTS FOR CTCL IN THE LANCET ONCOLOGY · Data to date demonstrate high activity and favorable safety profile in Sézary syndrome, an aggressive form [...]
Innate Pharma annonce la publication des résultats de l’essai de Phase I d’IPH4102 dans les LTC dans The Lancet Oncology
26/06/2019
INNATE PHARMA ANNONCE LA PUBLICATION DES RÉSULTATS DE L’ESSAI DE PHASE I D’IPH4102 DANS LES LTC DANS THE LANCET ONCOLOGY · Les données à ce jour font état d’un niveau d’activité élevé ainsi que d’un profil de tolérance [...]
Helsinn appoints Giorgio Calderari, Group General Manager and Chief Operating Officer, to the Board of Directors
26/06/2019
Helsinn appoints Giorgio Calderari, Group General Manager and Chief Operating Officer, to the Board of Directors Lugano, Switzerland, June 26, 2019: Helsinn, the Swiss pharmaceutical group focused on building quality [...]

Pages